MedTrace Logo

Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT

NCT04128917 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2021-05-12

No results posted yet for this study

Summary

This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Tegoprazan

Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral

DRUG

RAPAE01

RAPAE01/Clarithromycin/Amoxicillin BID peroral

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • JAEGYU KIM · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2020-12-21
Completion
2021-01-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04128917 on ClinicalTrials.gov